Literature DB >> 908756

Plasma calcitonin in normal man. Differences between men and women.

H Heath, G W Sizemore.   

Abstract

We measured plasma calcitonin concentrations in healthy volunteers (20 men, ages 23-45 yr, mean, 30 yr; 25 women, ages 21-46 yr, mean, 30 yr) with a radioimmunoassay capable of detecting 5 pg of calcitonin/500 mul incubation volume, or 25 pg/ml of unextracted plasma. All subjects had 4-h calcium infusion (15 mg Ca/kg), and 24 subjects had intravenous pentagastrin injection (0.5 mug/kg) on separate days. Men had higher basal plasma immunoreactive calcitonin concentrations than women (P < 0.001): mean, 49 pg/ml (range, <25-73) and 31 pg/ml (range, <25-51), respectively. 18 of the 20 men (90%) responded to induced hypercalcemia with increases in plasma immunoreactive calcitonin; only 14 of the 25 women (56%) responded. In men, the mean increase of plasma immunoreactive calcitonin+/-SE was 58+/-9 pg/ml, but for women was only 25+/-6 pg/ml. 8 of 10 men (80%) responded to pentagastrin with an increase of plasma immunoreactive calcitonin >30 pg/ml, compared with such a response in only 1 of 14 women (7%). These differences of plasma immunoreactive calcitonin responses between the sexes were statistically significant (calcium infusion, P < 0.02; pentagastrin, P < 0.001). The physiologic importance of these observations is unknown, but we speculate that a lifelong, relative deficiency of calcitonin in some women could play a role in age- and sex-related bone loss, particularly during the estrogen-deficient postmenopausal years.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908756      PMCID: PMC372466          DOI: 10.1172/JCI108865

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Human calcitonin radioimmunoassay in normal and pathological conditions.

Authors:  G Heynen; P Franchimont
Journal:  Eur J Clin Invest       Date:  1974-06       Impact factor: 4.686

2.  Plasma calcitonin levels in Japanese quail.

Authors:  J N Boelkins; A D Kenny
Journal:  Endocrinology       Date:  1973-06       Impact factor: 4.736

3.  Serum concentrations of estrogen, testosterone, and gonadotropins in osteoporotic and nonosteoporotic postmenopausal women.

Authors:  B L Riggs; R J Ryan; H W Wahner; N S Jiang; V R Mattox
Journal:  J Clin Endocrinol Metab       Date:  1973-06       Impact factor: 5.958

4.  Radioimmunoassay for bovine calcitonin.

Authors:  L J Deftos; J F Habener; G P Mayer; A E Bury; J T Potts
Journal:  J Lab Clin Med       Date:  1972-03

5.  Relative importance of parathyroid hormone and thyrocalcitonin in calcium homeostasis.

Authors:  L M Sherwood
Journal:  N Engl J Med       Date:  1968-03-21       Impact factor: 91.245

6.  The regulation of calcitonin in normal human plasma as assessed by immunoprecipitation and immunoextraction.

Authors:  J G Parthemore; L J Deftos; D Bronzert
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  Radioimmunoassay of calcitonin in human plasma.

Authors:  O L Silva; R H Snider; K L Becker
Journal:  Clin Chem       Date:  1974-03       Impact factor: 8.327

8.  Immunological stability of calcitonin in plasma.

Authors:  J F Habener; F R Singer; L J Deftos; J T Potts
Journal:  Endocrinology       Date:  1972-04       Impact factor: 4.736

9.  Immunoassay for human calcitonin. II. Clinical studies.

Authors:  L J Deftos; A E Bury; J F Habener; F R Singer; J T Potts
Journal:  Metabolism       Date:  1971-12       Impact factor: 8.694

10.  Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma.

Authors:  G W Sizemore; H Hpeath; J M Larson
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

View more
  40 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Circulating monomer-like calcitonin in osteoporotic patients.

Authors:  H Rong; M Sääf; O Tørring; U Sjöstedt; E Bucht
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

3.  Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients.

Authors:  P Schneider; P Berger; K Kruse; W Börner
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 4.  C-cell hyperplasia and medullary thyroid microcarcinoma.

Authors:  J A Albores-Saavedra; J E Krueger
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  Serum levels of calcitonin in Cushing's syndrome.

Authors:  G Luisetto; F Mantero; M Boscaro; L Tizian; M Zangari; D Ziliotto
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

6.  The surgical management of medullary thyroid carcinoma.

Authors:  C F Russell; J A Van Heerden; G W Sizemore; A J Edis; W F Taylor; W H ReMine; J A Carney
Journal:  Ann Surg       Date:  1983-01       Impact factor: 12.969

7.  Basal and pentagastrin-stimulated levels of calcitonin in thyroid and peripheral veins during normocalcemia and chronic hypercalcemia in humans.

Authors:  M Ericsson; M Berg; S Ingemansson; B Jernby; J Järhult
Journal:  Ann Surg       Date:  1981-08       Impact factor: 12.969

8.  The parathyroid glands in multiple endocrine neoplasia type 2b.

Authors:  J A Carney; S I Roth; H Heath; G W Sizemore; A B Hayles
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

Review 9.  Future horizons for calcitonin: a U.S. perspective.

Authors:  J H Carstens; J D Feinblatt
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

10.  Multiple endocrine neoplasia type 2 (Sipple's syndrome): clinical and cytogenetic analysis of a kindred.

Authors:  A Zatterale; M Stabile; V Nunziata; G Di Giovanni; R Vecchione; V Ventruto
Journal:  J Med Genet       Date:  1984-04       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.